Intravitreal triamcinolone acetonide for the treatment of cystoid macular edema secondary to Behçet disease.
OBJECTIVE
To evaluate the safety and effectiveness of intravitreal triamcinolone acetonide in patients with cystoid macular edema (CME) associated with Behçet disease.


METHODS
Interventional case series.


METHODS
Ten eyes of 10 patients with CME from Behçet disease made up the study population. All eyes had persistent CME despite medical treatment for at least 2 months. Intravitreal injection of 4 mg (0.1 ml) of triamcinolone acetonide was offered to treat macular edema. The visual and anatomic responses were observed.


RESULTS
At 1-month follow-up, a reduction in mean foveal thickness of 37.4%, from 416 microm to 260.5 microm, was attained. At 3-month follow-up, mean foveal thickness was 286.2 microm and at 6 months, 263.7 microm. No eyes had lost vision at 1 month, and eight eyes (80%) showed improvement in visual acuity. At 3-month and 6-month follow-up, three eyes (30%) remained stable and the other eyes had maintained the improved acuity.


CONCLUSIONS
Intravitreal triamcinolone acetonide is a promising therapeutic method for CME from Behçet disease.
Karacorlu
Murat
M
Istanbul Retina Institute, Istanbul, Turkey. retina@pobox.com
Mudun
Baki
B
Ozdemir
Hakan
H
Karacorlu
Serra Arf
SA
Burumcek
Engin
E
D000328:Adult; D001528:Behcet Syndrome / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D007267:Injections; D008269:Macular Edema / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D012449:Safety; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D014222:Triamcinolone Acetonide / Q000627:therapeutic use*; D014792:Visual Acuity; D014822:Vitreous Body
D005938:Glucocorticoids; D014222:Triamcinolone Acetonide